446880-81-5

Basic information

• Product Name: 2-BROMO-4-(3-PYRIDIN-2-YL-1H-PYRAZOL-4-YL)-PYRIDINE
• Synonyms: 2-BROMO-4-(3-PYRIDIN-2-YL-1H-PYRAZOL-4-YL)-PYRIDINE;2-bromo-4-(3-pyridin-2-yl-1H-pyrazol-yl)pyridine;2-bromo-4-(3-(pyridine-2-yl)-1H-pyrazol-4-yl)pyridine
• CAS NO: 446880-81-5
• Molecular Formula: C₁₃H₉BrN₄
• Molecular Weight: 301.14136
• Mol File: 446880-81-5.mol

Chemical Properties

• Boiling Point: 457.4±45.0 °C(Predicted)
• Appearance: /
• Density: 1.550±0.06 g/cm3(Predicted)
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 8.17±0.50(Predicted)
• CAS DataBase Reference: 2-BROMO-4-(3-PYRIDIN-2-YL-1H-PYRAZOL-4-YL)-PYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BROMO-4-(3-PYRIDIN-2-YL-1H-PYRAZOL-4-YL)-PYRIDINE(446880-81-5)
• EPA Substance Registry System: 2-BROMO-4-(3-PYRIDIN-2-YL-1H-PYRAZOL-4-YL)-PYRIDINE(446880-81-5)

Safety Data

• Hazardous Substances Data: 446880-81-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
2-Bromo-4-(3-pyridin-2-yl-1H-pyrazol-4-yl)pyridine is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows for the development of new drugs with potential therapeutic applications.
Used in Organic Synthesis:
2-BROMO-4-(3-PYRIDIN-2-YL-1H-PYRAZOL-4-YL)-PYRIDINE serves as a valuable building block in complex organic synthesis reactions. Its presence in the core structures of numerous medicinal chemistry applications makes it a versatile component in the creation of novel molecules with desired properties.
Used in Research and Development:
2-Bromo-4-(3-pyridin-2-yl-1H-pyrazol-4-yl)pyridine is employed in research and development settings to explore its potential applications and properties. Its role in the synthesis of new compounds and its interaction with other molecules can provide insights into its possible uses in various industries.

Upstream product

• 4926-28-7 2-Bromo-4-picoline 
• 2524-52-9 ethyl-2-picolinate 
• 446852-65-9 2-(2-bromopyridin-4-yl)-1-(pyridin-2-yl)ethan-1-one 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 

Downstream Products

• 1333492-76-4 1-methyl-4-(4-(3-(pyridin-2-yl)-1-trityl-1H-pyrazol-4-yl)pyridin-2-yl)piperazine 
• 1333492-75-3 2-(piperidin-1-yl)-4-(3-(pyridin-2-yl)-1-trityl-1H-pyrazol-4-yl)pyridine 
• 1333492-74-2 1-(4-(3-(pyridin-2-yl)-1-trityl-1H-pyrazol-4-yl)pyridin-2-yl)-1H-benzo[d]imidazole 
• 1333492-73-1 2-(1H-imidazol-1-yl)-4-(3-(pyridin-2-yl)-1-trityl-1H-pyrazol-4-yl)-pyridine 
• 1333492-72-0 2-(1H-pyrazol-1-yl)-4-(3-(pyridin-2-yl)-1-trityl-1H-pyrazol-4-yl)-pyridine 
• 1333492-71-9 4-(3-(pyridin-2-yl)-1-trityl-1H-pyrazol-4-yl)-2,2'-bipyridine 
• 1333492-70-8 6'-(4-methylpiperazin-1-yl)-4-(3-(pyridin-2-yl)-1-trityl-1H-pyrazol-4-yl)-2,3'-bipyridine 
• 1333492-69-5 N,N-dimethyl-3-((4-(3-(pyridin-2-yl)-1-trityl-1H-pyrazol-4-yl)-[2,3'-bipyridin]-6'-yl)-oxy)propan-1-amine 
• 1333492-68-4 8-(4-(3-(pyridin-2-yl)-1-trityl-1H-pyrazol-4-yl)pyridin-2-yl)quinoline 
• 1333492-67-3 2-(2-methoxyphenyl)-4-(3-(pyridin-2-yl)-1-trityl-1H-pyrazol-4-yl)pyridine 
• 1333492-66-2 2-(3-methoxyphenyl)-4-(3-(pyridin-2-yl)-1-trityl-1H-pyrazol-4-yl)pyridine 
• 1333492-65-1 2-(1-methyl-1H-pyrazol-4-yl)-4-(3-(pyridin-2-yl)-1-trityl-1H-pyrazol-4-yl)pyridine 
• 1333492-64-0 5-(4-(3-(pyridin-2-yl)-1-trityl-1H-pyrazol-4-yl)pyridin-2-yl)-pyrimidine 
• 1333492-63-9 3-(4-(3-(pyridin-2-yl)-1-trityl-1H-pyrazol-4-yl)pyridin-2-yl)-quinoline 

Relevant articles and documents

Formulated and/or co-formulated liposome compositions containing TFGB antagonist prodrugs useful in the treatment of cancer and methods thereof

Formulated and/or co-formulated liposomes (LNP) and solid-lipid nanoparticles (SLNP) comprising TB Prodrugs and methods of making the LNPs and SLNPs are disclosed herein. The TB prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit

ALK5 INHIBITOR CONJUGATES AND USES THEREOF

The present disclosure relates to targeted drug conjugates comprising ALK5 inhibitors and targeting moieties that direct the ALK5 inhibitors to cells involved in fibrosis and cancer, for example myofibroblasts, activated fibroblasts and transitioning fibr

ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES

The present disclosure relates to antibody-drug conjugates comprising ALK5 inhibitors and their uses.

ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES

The present disclosure relates to antibody-drug conjugates comprising ALK5 inhibitors and their uses.

ANTIB0DY-ALK5 INHIBITOR CONJUGATES AND THEIR USES

The present disclosure relates to antibody-drug conjugates comprising ALK5 inhibitors and their uses.

2-Phenyl and 2-heterocyclic-4-(3-(pyridin-2-yl)-1H-pyrazol-4-yl)pyridines as inhibitors of TGF-β1 and activin A signalling

Novel inhibitors of TGF-β1 and activin A signalling based on a 2-aryl-4-(3-(pyridin-2-yl)-1H-pyrazol-4-yl)pyridine pharmacophore have been synthesised. Compounds containing phenyl or aromatic nitrogen heterocycle substituents inhibited both types of signalling with HEK-293T cells in culture, with a selectivity preference for TGF-β1. Synthetic compounds containing pyridin-3-yl, pyrazol-4-yl, pyrazol-1-yl or 1H-imidazoyl-1-yl substituents exhibited structural and functional attributes suitable for further investigation related to the development of more potent TGF-β inhibitors.

Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N- (tetrahydro-2H-pyran-4-yl)benzamide (GW788388): A potent, selective, and orally active transforming growth factor-β type I receptor inhibitor

Inhibitors of transforming growth factor β (TGF-β) type I receptor (ALK5) offer a novel approach for the treatment of fibrotic diseases such as renal, hepatic, and pulmonary fibrosis. The optimization of a novel phenylpyridine pyrazole series (1a) led to the identification of potent, selective, and orally active ALK5 inhibitors. The cellular potency and pharmacokinetics profiles of these derivatives were improved and several compounds presented antifibrotic activity when orally administered to rats in an acute liver model of dimethylnitrosamine- (DMN-) induced expression of collagen IA1 mRNA, a major gene contributing to excessive extra cellular matrix deposit. One of the most potent ALK5 inhibitors identified in this chemical series, compound 13d (GW788388), reduced the expression of collagen IA1 by 80% at a dose of 1 mg/kg twice a day (b.i.d.). This compound significantly reduced the expression of collagen IA1 mRNA when administered orally at 10 mg/kg once a day (u.i.d.) in a model of puromycin aminonucleoside-induced renal fibrosis.